Patents by Inventor Aditya VENKATESH

Aditya VENKATESH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
    Publication number: 20240102011
    Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.
    Type: Application
    Filed: October 9, 2023
    Publication date: March 28, 2024
    Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
  • ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES
    Publication number: 20240033378
    Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.
    Type: Application
    Filed: April 13, 2023
    Publication date: February 1, 2024
    Inventors: ISABEL AZNAREZ, Enxuan JING, Jacob KACH, Aditya VENKATESH, Juergen SCHARNER, Baruch TICHO, Gene LIAU
  • OPA1 antisense oligomers for treatment of conditions and diseases
    Patent number: 11814622
    Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.
    Type: Grant
    Filed: April 21, 2023
    Date of Patent: November 14, 2023
    Assignee: STOKE THERAPEUTICS, INC.
    Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
  • OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
    Publication number: 20230287410
    Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 14, 2023
    Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
  • OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
    Publication number: 20230250429
    Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 10, 2023
    Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
  • ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES
    Publication number: 20210268667
    Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.
    Type: Application
    Filed: October 23, 2018
    Publication date: September 2, 2021
    Inventors: Isabel AZNAREZ, Enxuan JING, Jacob KACH, Aditya VENKATESH, Juergen SCHARNER, Baruch TICHO, Gene LIAU